Servicio de Hematología: Hospital Universitario e Instituto Biosanitario (IBSAL) de Salamana . Paseo de San Vicente 37007 Salamanca, Spain.
Mediterr J Hematol Infect Dis. 2012;4(1):e2012074. doi: 10.4084/MJHID.2012.074. Epub 2012 Nov 7.
Follicular lymphoma (FL) remains incurable despite advances in new strategies of treatment, including monoclonal antibodies (MoAb). Except for early stages, FL is characterized by responses to treatments and systematic relapses. The main objective in this disease is to achieve a better progression free survival (PFS) and to increase overall survival (OS), mainly in young patients. In order to improve the results of conventional chemotherapy, autologous stem cell transplant (ASCT) is a feasible treatment in these patients. In this moment, ASCT is not recommended as first line treatment, except for transformed FL, but is a good strategy as salvage therapy with an improved PFS and OS. New drugs have been introduced to enhance responses of ASCT, but nowadays they are not part of conventional conditioning regimen.
滤泡性淋巴瘤 (FL) 尽管在新的治疗策略方面取得了进展，包括单克隆抗体 (MoAb)，但仍然无法治愈。除了早期阶段，FL 的特征是对治疗有反应且会系统性地复发。在这种疾病中，主要目标是实现更好的无进展生存期 (PFS) 和增加总生存期 (OS)，主要是在年轻患者中。为了提高常规化疗的效果，自体干细胞移植 (ASCT) 是这些患者可行的治疗方法。目前，ASCT 不建议作为一线治疗，除非是转化型 FL，但作为挽救疗法，ASCT 具有改善的 PFS 和 OS，是一种很好的策略。已经引入了新的药物来增强 ASCT 的反应，但目前它们不属于常规预处理方案。
